SARS CoV 2 News and Research

RSS

Human immune repertoire may not commonly produce cross-neutralizing antibodies to coronaviruses

Patients infected with either severe acute respiratory syndrome coronavirus (SARS-CoV) or SARS-CoV-2 produce antibodies that bind to the other coronavirus, but the cross-reactive antibodies are not cross protective, at least in cell-culture experiments, researchers report May 17 in the journal Cell Reports.

18 May 2020

Tocilizumab improves survival in COVID-19 patients with ARDS

The current COVID-19 pandemic caused by the SARS-CoV-2 (severe acute respiratory syndrome coronavirus-2), has already nearly 4.8 million confirmed cases and more than 318,000 deaths.

18 May 2020

Common mutations in SARS-CoV-2 related to non-variable segments of structural proteins

The ongoing severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pandemic is thought to have originated from an animal species, most likely bats, which succeeded in crossing over to humans. However, the exact species of origin has not yet been confirmed.

18 May 2020

Local variations in climate not likely to drive early COVID-19 pandemic

Local variations in climate are not likely to dominate the first wave of the COVID-19 pandemic, according to a Princeton University study published May 18 in the journal Science.

18 May 2020

Potential new treatment approach to fatal COVID-19

Researchers from the University of Colorado Anschutz Medical Campus and Pathways Bioscience in the United States have found that activating a transcription factor involved in oxidative stress regulation, antiviral activity, and inflammation may serve as a new treatment approach to coronavirus disease 2019 (COVID-19).

18 May 2020

SMART researchers awarded NMRC funding to develop rapid paper-based COVID-19 tests

Singapore-MIT Alliance for Research and Technology, MIT's research enterprise in Singapore, has received a grant from the National Medical Research Council COVID-19 Research fund for the acceleration of research and development of rapid paper-based serological and diagnostic tests for COVID-19.

18 May 2020

Novel insights on SARS-CoV-2 cell entry may inform further vaccine and treatment development

A research group from Harvard Medical School reported two cryo-electron microscopy structures derived from a single preparation of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) spike (S) protein in their paper available on the preprint server bioRxiv. Understanding the nuances of prefusion and postfusion conformations shed light on viral cell entry and may, in turn, guide the development of vaccines and drugs.

18 May 2020

Cigarette smoke spurs the lungs to make more SARS-CoV-2 receptors

New research from CSHL scientists suggests that cigarette smoke spurs the lungs to make more ACE2 (angiotensin-converting enzyme 2), the protein that the coronavirus responsible for COVID-19 grabs and uses to enter human cells.

18 May 2020

Cross-neutralization of SARS and COVID-19 coronaviruses by a monoclonal antibody

An antibody first identified in a blood sample from a patient who recovered from Severe Acute Respiratory Syndrome in 2003 inhibits related coronaviruses, including the cause of COVID-19.

18 May 2020

Study aims to identify markers that predict how COVID-19 affects patients

COVID-19 is the UK's largest public health crisis since World War II. There is an urgent need to identify why some patients with the virus do very well whereas others need to be admitted to intensive care and may die from the disease.

18 May 2020

University of Valencia files patent application for COVID-19 vaccine

The University of Valencia has filed a patent application for a vaccine candidate against COVID-19, developed by a research team from the Department of Microbiology

18 May 2020

COVID-19 may lead to thrombosis in the lungs and subsequently multi organ failure

COVID-19, the disease caused by SARS-CoV-2, not only may lead to severe pneumonia but also to thrombosis in the lungs and, subsequently, to multi organ failure involving kidneys, liver and pancreas.

18 May 2020

Avacta's SARS-COV-2 neutralizing Affimer reagents show therapeutic potential for COVID-19

Avacta Group plc, the developer of Affimer biotherapeutics and reagents, is pleased to announce that several of the Affimer reagents recently generated for development of a point-of-care COVID-19 antigen saliva test have now also been shown to block the interaction between the virus’ spike protein and ACE2, a receptor on human cells that is key to the virus infection pathway.

From Avacta Life Sciences Ltd. 18 May 2020

Research explores how human enzymes could be used to exacerbate COVID-19

Centenary Institute researchers have examined the critical role of human enzymes and the coronavirus in a newly published scientific review article that explores potential strategies for COVID-19 disease treatment and management.

18 May 2020

Oxford University vaccine prevents SARS-CoV-2 pneumonia in rhesus macaques

As the world continues to grapple with the coronavirus pandemic, many scientists, institutions, and pharmaceutical companies are working hard to develop an effective vaccine.

18 May 2020

Kawasaki disease outbreak in children with COVID-19

The ongoing COVID-19 pandemic has marched its way to almost all parts of the world, with hundreds of thousands of deaths and over 4.5 million cases as of May 15, 2020. One saving grace has been the apparent sparing of children, though the mortality in older people is quite high.

17 May 2020

Host-virus interaction drives adaptive mutation in bat CoV related to SARS-CoVs

Virus and receptor diversity is shaped by the need to evolve advanced weaponry to facilitate virus entry and infection, on the one hand, and host resistance, on the other. A new paper published on the preprint server bioRxiv* shows how this mechanism operates in a bat coronavirus, which is related to the earlier SARS coronavirus.

17 May 2020

Inadequate vaccine and epidemic control in the US

A new paper published on the preprint server medRxiv* in May 2020 shows that vaccination must be combined with nonpharmacological interventions (NPIs) to achieve rapid and effective control of the ongoing pandemic.

17 May 2020

New and unexplored angle in the binding of SARS-CoV-2 to host cells

Researchers in the Netherlands, Cuba, and Italy have made important discoveries about the carbohydrate-mediated binding of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) spike protein to host cell lectin receptors and host lung microbiota.

17 May 2020

Well-known cancer drugs may prevent SARS-CoV-2 viral replication say researchers

Researchers in Frankfurt, Germany, have described cell signaling events that occur when severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infects host cells and have identified pathways that are essential for the virus to replicate.

17 May 2020

SARS CoV 2 News and Research

Human immune repertoire may not commonly produce cross-neutralizing antibodies to coronaviruses

Tocilizumab improves survival in COVID-19 patients with ARDS

Common mutations in SARS-CoV-2 related to non-variable segments of structural proteins

Local variations in climate not likely to drive early COVID-19 pandemic

Potential new treatment approach to fatal COVID-19

SMART researchers awarded NMRC funding to develop rapid paper-based COVID-19 tests

Novel insights on SARS-CoV-2 cell entry may inform further vaccine and treatment development

Cigarette smoke spurs the lungs to make more SARS-CoV-2 receptors

Cross-neutralization of SARS and COVID-19 coronaviruses by a monoclonal antibody

Study aims to identify markers that predict how COVID-19 affects patients

University of Valencia files patent application for COVID-19 vaccine

COVID-19 may lead to thrombosis in the lungs and subsequently multi organ failure

Avacta's SARS-COV-2 neutralizing Affimer reagents show therapeutic potential for COVID-19

Research explores how human enzymes could be used to exacerbate COVID-19

Oxford University vaccine prevents SARS-CoV-2 pneumonia in rhesus macaques

Kawasaki disease outbreak in children with COVID-19

Host-virus interaction drives adaptive mutation in bat CoV related to SARS-CoVs

Inadequate vaccine and epidemic control in the US

New and unexplored angle in the binding of SARS-CoV-2 to host cells

Well-known cancer drugs may prevent SARS-CoV-2 viral replication say researchers

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Expanding access to NMR with the Fourier 80 Duo

Latest News